We speak about IBD as a generalized group, but in reality there are at least two distinct subtypes: Ulcerative Colitis and Crohn’s Disease. While other subtypes exist, these two are the main categories under which most patients fall, with Ulcerative Colitis primarily impacting the large intestine and the rectum, while Crohn’s Disease can impact anywhere along the GI tract from mouth to anus, but more commonly the terminal ileum (end of the small intestine) and/or the colon. This is a general rule, and as with anything in medicine, there are many exceptions; however, when it comes to treatment, the differences and distinctions between these two groups are essential for doctors to know how to begin treatment.
Ulcerative Colitis, in contrast to Crohn’s Disease, is relatively well understood, with thousands of studies investigating different treatments and therapies to address underlying causes.
In a first of its kind study, the use of CurQD®, a combination curcumin-Qing Dai nutraceutical developed by Evinature, was investigated in mild-to-moderate Crohn’s Disease. Patients were given CurQD® and monitored over a 8-12 week induction period, where symptoms and clinical biomarkers were measured and analyzed. The results confirmed that CurQD® significantly and successfully induced clinical and biomarker remission in Crohn’s Disease patients, including many patients that had prior experience taking biologics. While further research is required for specific subtypes of Crohn’s Disease, the scientific evidence confers good news for Crohn’s Disease patients, providing another pathway of enhancing treatment outcomes through supplementing existing treatment with CurQD®, or as a stand-alone gut-targeted protocol.
This study has been presented at a number of conferences, including but not limited to the ECCO Conference and DDW 2025, two of the largest international conferences for GI experts, biotech pioneers, pharmaceutical representatives, and patient group advocates to come together to discuss the latest and greatest advances in IBD and other gastrointestinal disorders.
We at Evinature are committed to bringing cutting-edge, science-backed nutraceutical options to you, the patient, with personalized, gut-targeted protocols available through our home page. You can check out our shop here, or take our free online gut health assessment to see which of our protocols are right for you and your gut!
References:
Summer Pitocchelli-Schwartzman
